Extensive pharmaceutical & life sciences experience. Former Corporate VP of Syntex (now Roche), and CEO of five other companies, one he took public, raising $46M. Background includes marketing, finance, fund raising, R&D, Technical Transfer, product development and clinical trials. Holds several patents. Ph.D. in Biochemistry/Physiology from U. of Cambridge, two B.S. degrees from U. of London, and is a Fellow of the Royal Society of Medicine.

Mark is a 1971 graduate of the U. of Alabama. He and his wife, Alyson, cofounded Pharmabiotix in 2006. He helped to develop and market SymbionTM and is coholder of one EU and 5 US patents. He provided input for the clinical trial protocol to Dr. Richard Fedorak of the U. of Alberta and to Health Canada. Prior experience includes 18 years as a pharmaceutical executive recruiter and founder of Cobb & Company LLC.

Founder of Hultquist IP, issuing nearly 1,000 patents for his clients since 1976. Holds a B.S. & M.S. of Science Degrees in Chemical Engineering from Washington U. & law degree from Fordham U. (member of Sigma XI). Is a co-inventor of 7 patents. Has extensive experience in patent litigation & licensing deals for major corporations & pharmaceutical companies. Is an IP expert witness in U.S. District Court & filed briefs w/ the U.S. Supreme Court.

Professor of Medicine, Div. of Gastroenterology & Assoc. VP Research, U. of Alberta. A recipient of many awards, research fellowships & grants, he is a recognized expert in inflammatory bowel disease. He serves on many national & international scientific advisory boards. He has published over 400 peer-reviewed manuscripts, holds 2 patents, & lectures around the world. Received M.D. degree with first class honors from the U. of Alberta in 1978.